Kornimate/medical-research-clean huggingface dataset:
osteogenesis and dental eruption through electrical stimuli

Conditions: Cleft Lip

Summary: the closure of the alveolar cleft as part of cleft lip and palate deformities is a procedure that, to this date, still demands great efforts from plastic surgeons. the feasibility of periosteoplasty for reconstruction of the alveolar arcade as well as the use of electrical stimulation in order to increase osteoneogenesis have been proven in the past. the present study attempts to combine both procedures that have only been reported separately worldwide. the objective of this study is to increase the osteogenic capacity and hence, dental eruption.


Eligibility criteria:
inclusion criteria: * patients with unilateral cleft lip and palate deformities and alveolar defects exclusion criteria: * patients without alveolar cleft * patients with syndromes that did not require periosteoplastic procedures as well as patients with systemic illnesses that may affect the result of the study (for instance diabetes)

Keywords: osteogenesis [g07.700.320.500.325.377.625.100.729] tooth eruption [g10.549.235.726]
non-interruptive alerts for improving use of clinical decision rules

Conditions: Pulmonary Embolism; Deep Vein Thrombosis; Minor Head Injury; Chest Pain; Neck Trauma

Summary: this study is an extension of a planned quality improvement project that aims to promote standard of care by increasing the use of evidence-based clinical decision rules amongst emergency medicine providers in the university of utah emergency department. patient-specific information from the ehr will be used to recommend the use of relevant clinical decision rules to emergency medicine providers at the point-of-care. these recommendations will be in the form of non-interruptive alerts with one-click access to the suggested decision rules through the mdcalc connect ehr add-on application. specific aims of the study are to determine if 1) patient-specific non-interruptive alerts increase the use of clinical decision rules amongst emergency medicine providers and 2) an increase in the use of clinical decision rules affects provider ordering habits.


Eligibility criteria:
patient inclusion criteria: * 16 years of age or older * qualifying chief complaint\* patient exclusion criteria: * none * a full list of the qualifying chief complaints is provided in appendix a of the full research protocol.

Keywords: clinical decision support clinical decision rules
neuronal excitability of hcn1 channel mutations in dravet syndrome

Conditions: Dravet Syndrome

Summary: this study addresses the changes in the axonal excitability parameters. it will compare these changes in patients with early infantile epileptic encephalopathy with hcn1 channel mutation and in control patients, with and without epilepsy.


Eligibility criteria:
inclusion criteria: * early infantile epileptic encephalopathy with hcn1 channel mutation * control patients with no neurologic pathology (age, gender and body temperature matched) * epileptic patients (age, gender and body temperature matched) exclusion criteria: * pregnant or breast feeding patient
bariatric arterial embolization for morbid obesity

Conditions: Morbid Obesity

Summary: the purpose of this study is to evaluate the safety and effectiveness of left gastric artery embolization(bariatric arterial embolization) for morbid obesity. when the target vessel is blocked, some of the body's signals for feeling hungry will be suppressed and lead to weight loss. although there are many ways to treat morbid obesity, surgery is currently the only effective method to be confirmed. but surgical treatment is likely to carry a high risk of treatment-related complications, such as fistula or intestinal obstruction, etc. this study is designed to help treat obesity using a method of transvascular interventional therapy, which is minimally invasive and non-surgical.


Eligibility criteria:
inclusion criteria: 1. body mass index (bmi) \>30. 2. no history of gastrointestinal surgery. 3. willing, able and mentally competent to provide written informed consent. 4. suitable for protocol therapy as determined by the interventional radiology investigator. 5. adequate hematological, hepatic and renal function as follows: hematological neutrophils \> 1.5 x 109/l platelets \> 100 x 109/l inr \ 60ml/min.1.73m2 6. aged between18 and 65 years old. 7. more than one year's follow-up can be obtained reliably exclusion criteria: 1. prior history of gastric pancreatic, hepatic, and/or splenic surgery 2. prior embolization to the stomach, spleen or liver 3. prior or current history of peptic ulcer disease 4. significant risk factors for peptic ulcer disease including daily nsaid use and smoking. 5. portal venous hypertension or cirrhosis 6. less than 18 years or older than 65 years of age 7. known aortic pathology such as aneurysm or dissection renal insufficiency as evidenced by an estimated glomerular filtration rate of \< 60 milliliters per minute an estimated glomerular filtration rate of \< 60 milliliters per minute 8. major comorbidity such as cancer, significant cardiovascular disease, or peripheral arterial disease 9. pregnant or intend to become pregnant within one year known history of allergy to iodinated contrast media 10. patients with certain psychiatric disorders such as schizophrenia, borderline personality disorder, and uncontrolled depression, and mental/cognitive impairment that limits the individual's ability to understand the proposed therapy. 11. patients currently taking or requiring chronic use of nsaid or steroid medications

Keywords: left gastric artery embolization obesity
figitumumab combined with pegvisomant for advanced solid tumors

Conditions: Colorectal Neoplasms; Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Sarcoma

Summary: this is a phase 1 study investigating the safety and tolerability of figitumumab plus pegvisomant for treatment of advanced solid tumors.

this study was closed to enrollment on 18 april 2011 due to inability to recruit patients on a timely basis as well as business reasons. study closure was not related to any safety concerns.

Eligibility criteria:
inclusion criteria: * patients ≥18 years of age with advanced solid tumors for which the combination of figitumumab and pegvisomant are reasonable treatment options. * patients between the ages of 10 and 18 years with advanced sarcomas for which there is no available curative therapy or therapy proven to prolong survival with an acceptable quality of life will be included in the sarcoma expansion cohort. * adequate recovery from prior therapies. * adequate organ function (i.e. bone marrow, kidney, liver) * total igf-1 ≥100 ng/ml (13 nmol/l). exclusion criteria: * concurrent treatment with any anti-tumor agents. * pregnant or breastfeeding females. * significant past history or active cardiac disease * active infection * history of diabetes mellitus. * glycosylated hemoglobin \>5.7

Keywords: advanced solid tumors cancer refractory cancer figitumumab pegvisomant
patient activated controlled expansion (pace) trial

Conditions: Breast Cancer; Mastectomy; Breast Reconstruction

Summary: the purpose of this study is to determine whether a patient controlled tissue expander can improve the results and patient experience in breast reconstruction. the study hypothesis is that patient controlled expansion will lead to rapid and more comfortable outcomes than historical precedents.

title: patient activated controlled expansion (pace) for breast reconstruction utilizing controlled co2 inflation design: prospective, open-label, single-arm, feasibility trial purpose: to evaluate the airxpanders tissue expander in patients undergoing breast reconstruction surgery following mastectomy. enrollment: this feasibility trial will enroll up to 10 patients. following enrollment of the first 5 patients, the sponsor will determine if additional subjects will be recruited to further evaluate treatment outcome. clinical sites: up to 3 sites and 3 surgeons will participate in this study. the surgeon(s) should have the necessary qualifications and sufficient experience (minimum of 12 breast tissue expanders placed per year) to participate in the trial. duration of patient participation: eligible patients will be enrolled over approximately 2 months. patients will be instructed on the tissue expansion protocol pre-operatively and undergo post-operative clinical follow-up on a weekly basis or more frequently if deemed necessary by the treating surgeon. each patient will be followed through removal of the tissue expander. study population: the study population will consist of up to 10 patients. eligible patients are females between the ages of 18 and 65 years who are planning to undergo breast reconstruction surgery following mastectomy. eligible patients must be able to provide informed consent and understand protocol components.

Eligibility criteria:
inclusion criteria: 1. female between the ages of 18 and 65 years. 2. planned breast reconstruction surgery post-mastectomy. 3. able to provide informed consent. 4. able to understand protocol components. exclusion criteria: 1. tissue at the intended expansion site is determined unsuitable by the surgeon (i.e., infection, compromised vascularity, history of compromised wound healing, mastectomy skin flaps of questionable viability, excessively tight skin envelope, previous radiation treatment, active ulceration) 2. residual gross tumor at the intended expansion site 3. history of or planned adjuvant radiation therapy 4. co-morbid condition determined by the surgeon to pose unduly high risk of surgical and/or postoperative complications. 5. obesity with bmi of 30 or above 6. current smoker 7. psychologically unsuitable patient 8. patient unable to understand the protocol for tissue expansion 9. planned flight or assent to altitude exceeding 1000 meters above baseline during the expansion period.

Keywords: cancer breast cancer mastectomy breast reconstruction reconstruction tissue expansion two-stage breast reconstruction tissue expander aeroform airxpander
laparoscopic uterine sparing techniques outcomes and reinterventions

Conditions: Uterine Fibroids; Myomas

Summary: the purpose of this study is to compare the outcomes of two uterine-conserving treatment alternatives for symptomatic uterine fibroids: laparoscopic myomectomy (lm) and global fibroid ablation (gfa) using the halt system. laparoscopic ultrasound (lus) is a standard step prior to the gfa procedure but has not been a standard step prior to lm. incorporating laparoscopic ultrasound as a first step prior to both treatments allows the surgeon to have equal access to valuable imaging information and to plan treatment accordingly. by randomizing the subject immediately after laparoscopic ultrasound, selection bias toward one treatment or the other following the lus is eliminated.


Eligibility criteria:
inclusion criteria: * are ≥ 18 years old and menstruating * have symptomatic uterine fibroids * have a uterine size ≤16 gestational weeks as determined by pelvic exam * have fibroids that are less than 10 cm in any diameter * desire uterine conservation * have had a normal papanicolaou test (pap smear) (i.e. pap i or pap ii) at the latest pre-study examination and no longer than 36 months before study entry. * are willing and able to comply with all study tests, procedures, and assessment tools * are capable of providing informed consent. exclusion criteria: * have contraindications for laparoscopic surgery and/or general anesthesia. * are expected to be high risk for, or are known to have, significant intra-abdominal adhesions (defined as adhesions that would require extensive dissection to mobilize and view all surfaces of the uterus) * patients requiring major elective concomitant procedures (e.g., hernia repair, hysteroscopic resection, endometrial ablation, uterine artery ligation, etc.) that could confound the results of the study * are pregnant or lactating * have taken any depot gonadotropin-releasing hormone (gnrh agonist within three months prior to the screening procedures * have an implanted intrauterine or fallopian tube device for contraception that cannot or will not be removed at least ten days prior to treatment * have chronic pelvic pain not due to uterine fibroids * have known or suspected endometriosis or adenomyosis * have active or history of pelvic inflammatory disease * have a history of, or evidence of, gynecologic malignancy or pre-malignancy within the past five years * have had pelvic radiation * have a non-uterine pelvic mass over 3 cm * have a cervical myoma * have one or more completely intracavitary submucous fibroids (type 0) or only type 0/1 submucous fibroids that are better treated via hysteroscopic methods * in the medical judgment of the investigator should not participate in the study * are not willing to be randomized to treatment.

Keywords: symptomatic uterine fibroids menorrhagia heavy bleeding myomas radiofrequency ablation rfa leiomyoma fibroids
ombitasvir /paritaprevir/ritonavir plus ribavirin on hcv gt4

Conditions: Hepatitis C Virus Infection

Summary: the objective of the investigators was to delineate the efficacy and safety of ombitasvir, paritaprevir with ritonavir (obv/ptv/r) plus ribavirin (rbv) on chronic hcv gt4 egyptian naïve patients

direct-acting antivirals (daas) combination therapies from various mechanisms of action and families have been revolutionized the management landscape of chronic hepatitis c virus (hcv). ombitasvir, paritaprevir with ritonavir (obv/ptv/r) ± ribavirin (rbv) are approved to treat hcv genotype 4 (gt4) infection. here, investigators' objective was to delineate the efficacy and safety of obv/ptv/r plus rbv of hcv gt4 in the treatment of egyptian naïve patients. between 5 january and 8 september 2017, a cohort of 100 egyptian patients infected with hcv gt4 was allocated and administered orally obv/ptv/r with rbv, for 12 weeks, which given as oral tablets based on patient tolerability. the primary endpoint of investigators' study was a sustained virological response (hcv rna \< 12 iu/ml) 12 weeks from the cessation of the treatment (svr12).

Eligibility criteria:
inclusion criteria: treatment-naïve patients with hcv gt4 with plasma hcv rna level \>10,000 iu/ml exclusion criteria: * hepatitis of non-hcv cause * coinfection with other than hcv gt4 * poorly controlled diabetics (hba1c \>8) patients * a history of extra-hepatocellular malignancy in the last 5 years * major severe illness such as congestive heart failure, respiratory failure, evidence of hepatic decompensation. * laboratory and blood picture abnormalities such as anemia (hemoglobin concentration of 10 \ 2.3, serum total bilirubin concentration of \>3.0 mg/dl.

Keywords: ombitasvir paritaprevir ritonavir ribavirin hcv genotype 4 naïve egyptians
technolas 217z laser with zyoptix aspheric algorithm used for the lasik treatment of myopia and myopic astigmatism.

Conditions: Myopia; Astigmatism

Summary: the purpose of this study is to evaluate the safety and effectiveness of the bausch \& lomb technolas 217z laser with the investigational zyoptix aspheric algorithm when used for lasik treatment of myopia and myopic astigmatism.


Eligibility criteria:
inclusion criteria: * subjects who were of legal age (at least 18) and had full legal capacity to volunteer. * subjects must be willing to have both eyes treated with the laser. * subjects must have up to -12.00d of absolute spherical myopia (not spherical equivalent) with up to -6.00d of refractive astigmatism, with a spherical equivalent up to -15.00d as measured by manifest subjective refraction. * subjects who had less than 0.75 d of difference in the preoperative manifest spherical equivalent and cycloplegic spherical equivalent subjective refractions. (manifest subjective refractions adjusted for optical infinity were used.) * high contrast, manifest best spectacle-corrected distance logmar visual acuity correctable to at least 0.3 in both eyes, and must not differ between eyes by more than 1 line (5 letters). * contact lens wearers must have 2 orbscan measurements and 2 manifest subjective refractions taken preoperatively at least 1 week apart. * contact lens wearers must have gas permeable lenses discontinued for at least 3 weeks and soft lenses discontinued for at least 2 weeks prior to the preoperative evaluation. exclusion * subjects with uncorrected visual acuity better than 20/40 (snellen) or 0.3 logmar * subjects who were immuno-compromised or had a diagnosis of connective tissue disease, clinically significant atopic disease, diabetes, autoimmune diseases and other acute or chronic illnesses that increased the risk to the subject or could have confounded the outcomes of this study. * subjects with uncontrolled glaucoma or glaucoma who were under treatment in the study eye or with ocular hypertension. * subjects who demonstrated evidence of retinal vascular disease. * subjects who have an ocular muscle disorder including strabismus or nystagmus, or other disorders that affected fixation. * subjects who were at risk for angle closure or who had a potentially occludable angle, as evidenced by a shallow anterior chamber on slit lamp exam, confirmed by gonioscopy as deemed necessary by the study investigator. * subjects who had undergone previous intraocular or corneal surgery of any kind, including any type of excimer laser surgery for either refractive or therapeutic purposes. * subjects who were taking systemic medications likely to affect wound healing such as corticosteroids or anti-metabolites or any other medications that may increase the risk to the subject or confound the outcomes of this study. * subjects for whom the combination of their preoperative corneal thickness and the planned operative parameters for the lasik procedure could have resulted in less than 250 microns of remaining posterior corneal thickness below the flap postoperatively.
intensified treatments for patients with locally advanced nasopharyngeal carcinoma with detectable ebv dna after one cycle gp regime neoadjuvant chemotherapy

Conditions: Nasopharyngeal Carcinoma

Summary: the goal of this multicenter randomized non-inferior study is to compare the additon of camrelizumab or nimotuzumab to neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma patients whose ebv dna remained detectable after one cycle neoadjuvant chemotherapy using gp regimen. the main question it aims to answer is: whether the addition of carrilizumab or nituzumab improve the treatment outcomes in the relatively poor prognostic patients identified by the response of ebv dna. participants will be randomized to the combination of carrilizumab and standard treatment , the combination of nituzumab and standard treatment or the standard treatment alone if their ebv dna didn't decrease to undetectable level post first cycle of neoadjuvant chemotherapy.


Eligibility criteria:
inclusion criteria: 1. patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, type of who ii or iii, egfr+. 2. age 18-70 years. 3. clinical stage iii-iva (based on the 8th american joint committee on cancer\[ajcc\] edition). 4. patients with detectable pre-treatment plasma ebv dna which remained detectable after one cycle neoadjuvant. 5. ecog (eastern cooperative oncology group) score: 0-1 6. hemoglobin (hgb) ≥90 g/l, white blood cell (wbc) ≥4×109 /l, platelet (plt) ≥100×109 /l. 7. liver function: alanine transaminase(alt), aspartate aminotransferase(ast)\< 1.5 times the upper limit of normal value (uln), total bilirubin \<1.0×uln. 8. renal function: serum creatinine \<1×uln. 9. patients must sign informed consent and be willing and able to comply with the requirements of visits, treatment, laboratory tests and other research requirements stipulated in the research schedule. exclusion criteria: 1. histologically confirmed keratinizing squamous cell carcinoma (who i) 2. suffered from other malignant tumors (except the cure of basal cell carcinoma or uterine cervical carcinoma in situ) previously. 3. receiving radiotherapy or chemotherapy or targeted therapy previously 4. women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. 5. patients with significantly lower heart, liver, lung, kidney and bone marrow function. 6. severe, uncontrolled medical conditions and infections. 7. at the same time using other test drugs or in other clinical trials. 8. refusal or inability to sign informed consent to participate in the trial. 9. emotional disturbance or mental

Keywords: ebv dna camrelizumab nimotuzumab
fluid intake application to reduce kidney stone risks

Conditions: Kidney Stone

Summary: the purpose of this investigation is to prospectively evaluate the benefit of different methods of educating patients regarding their fluid intake through a readily available daily cellular phone application to improve overall urine output and reduce risk factors for stone recurrence.

the prevalence of kidney stone disease in the united states is increasing. recurrence of kidney stone disease has been reported as high as 50% at five years. urine supersaturation is a predominant factor in the formation of crystallization and stone disease and is dependent on fluid volume. high fluid consumption that dilutes the urine has been shown both in vitro and in clinical studies to reduce the tendency for stone crystallization as well as effectively decrease stone recurrence. as a result, water intake greater than two liters per day is a common initial therapy for prevention of stone disease. however, studies have shown that despite physician counseling most patients are only able to modestly increase their urine volume through fluid intake. this finding may be due to a discrepancy in patient perception of their actual fluid intake and resulting urine volume. the purpose of this investigation is to prospectively evaluate the benefit of different methods of educating patient regarding their fluid intake through a readily available daily cellular phone application to improve overall urine output and reduce risk factors for stone recurrence.

Eligibility criteria:
inclusion criteria: 1. patients ≥ 18 years old 2. seen in urology or nephrology clinic at unc with a diagnosis of kidney stone 3. prior 24-hour urine result with volume less than 2 to 2.5 liters exclusion criteria: 1. patient without cellular phone capable of utilizing android / apple application 2. patient already using some form of monitoring fluid intake / volume 3. inability to take fluid by mouth 4. patient with urinary diversion, chronic diarrhea, bowel diversion or other forms of excessive fluid loss 5. inability to obtain informed consent 6. non-english speaking
a survey study to see if patients diagnosed with parkinson's disease have higher incidence of melanoma

Conditions: Parkinson's Disease; Malignant Melanoma

Summary: patients with parkinson's disease will be seen by a dermatologist who will biopsy any suspicious skin lesions.


Eligibility criteria:
inclusion criteria: confirmed diagnosis parkinson's disease patient able and willing to give informed consent patient must not be taking any investigational drug at the time of enrollment exclusion criteria: unconfirmed, undocumented parkinson's disease unable to give consent taking any investigational product